Clinical trials: Early Stage Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
- Trial name
- NCT04025879
- Testing
- Nivolumab, Carboplatin, Cisplatin
- Where
- 108 sites in United States, Argentina and 20 more
- Volunteers
- 461 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer.
- Trial name
- NCT00062907
- Testing
- Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Corixa Corporation
Non Small Cell Lung Cancer, Interstitial Lung Disease
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease
This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes.
- Trial name
- ASPIRE-ILD (NCT03485378)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- 6 sites in Canada, United Kingdom
- Volunteers
- 39 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-small Cell Lung Cancer
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects.
- Trial name
- NCT00888823
- Testing
- Stereotactic Radiotherapy
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06498635
- Testing
- Biospecimen Collection, Computed Tomography, Durvalumab
- Where
- 282 sites in United States
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer(NSCLC)
the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis.
- Trial name
- CTC-TCM-FZ (NCT02603003)
- Testing
- JinFuKang, Cisplatin, Pemetrexed
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Non Small Cell Lung Cancer
Evaluation of Lymph Node Analysis Using One Step Nucleic Acid Amplification (OSNA) in Patients With Lung Cancer Who Underwent Robotic Lung Resection, Comparison With Traditional Methods
This prospective study aims to evaluate the effectiveness of the One-Step Nucleic Acid Amplification (OSNA) technique for detecting micrometastases in lymph nodes of patients with clinical stage I-II non-small cell lung cancer…
- Trial name
- LALC (NCT07301983)
- Testing
- lymph node analysis using the OSNA assay
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Lung Cancer
Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer
This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment.
- Trial name
- NCT03706027
- Testing
- radiation therapy-3 fractions, Radiation therapy-5 fractions
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Rochester
Non-small Cell Lung Cancer
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Stereotactic body radiation therapy (SBRT) is a special form of treatment which pinpoints high doses of radiation directly to cancer.
- Trial name
- NCT01525446
- Testing
- SBRT with proton beam radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer
VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer
Surgery may be the best treatment choice for early stage non-small cell lung cancer. And VATS major lung resection have been preferred as a standard radical procedure for early stage non-small cell lung cancer (NSCLC).This study…
- Trial name
- NCT01707888
- Testing
- Thoracoscopy/VATS
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University People's Hospital
Non-small Cell Lung Cancer
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
- Trial name
- RADIANT (NCT00373425)
- Testing
- Erlotinib
- Where
- 295 sites in United States, Argentina and 17 more
- Volunteers
- 1,252 people
- Sponsor
- OSI Pharmaceuticals
Early Lung Cancer
Serplulimab Combined With Cryoablation for Early-Stage Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if serplulimab combined with cryoablation can effectively treat early-stage non-small cell lung cancer (NSCLC) in adults who are not eligible for or decline surgery or radiotherapy.
- Trial name
- NCT07064876
- Testing
- Serplulimab, CT-guided Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xi Junjie
Lung Cancer
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as…
- Trial name
- DIASTAG (NCT06842056)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01935336
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Colorado, Denver
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC
Rationale: An anatomical surgical resection is considered to be the standard of care in fit patients who present with early stage non-small cell lung cancer (NSCLC).
- Trial name
- HAMLET (NCT02488850)
- Testing
- Surgery, SABR
- Where
- 3 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Non Small Cell Lung Carcinoma
Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer
The optimal strategy in advanced non small cell lung cancer with stable disease is not well known. There is no published study assessing an early change of chemotherapeutic drugs in these patients.Accordingly, we conduct this…
- Trial name
- NCT00199758
- Testing
- cisplatin, Gemcitabine, Taxol
- Where
- 21 sites in France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Limoges
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Early Stage Non-small-cell Lung Cancer (Stage 1-2)
Assessment of Ergonomics in 3D vs 2D Thoracoscopic Lobectomy
Video-assisted thoracic surgery (VATS) pulmonary lobectomy is currently widely employed as the first treatment option for surgical management of early stage (stage I-II) non-small-cell-lung-cancer (NSCLC).
- Trial name
- NCT03925103
- Testing
- 3D VATS lobectomy, 2D VATS lobectomy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Rome Tor Vergata
Lung Cancer, Thromboembolism
Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer.
- Trial name
- NCT00519805
- Testing
- dalteparin, quality-of-life assessment
- Where
- 60 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- Velindre NHS Trust